• Capricor Therapeutics (NASDAQ:CAPR) Upgraded to “Buy” by Zacks Investment Research

    Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued …

    Read More
  • 0 0